Private Equity Round in 2019
WCG is a prominent provider of regulatory and ethical review services for human research, focusing on enhancing the quality and efficiency of clinical studies. The company reviews new research protocols and offers a range of services including clinical and human gene therapy research, laboratory biosafety consulting, and solutions for human research protections. WCG also provides online learning resources, an electronic informed consent solution to streamline clinical processes, oncology review services, and a cloud-based platform for managing research activities. Serving a diverse clientele that includes large pharmaceutical companies, biotechnology firms, and contract research organizations, WCG is committed to accelerating the delivery of new treatments while upholding high standards of human subject protection. Founded in 2012 and headquartered in Princeton, New Jersey, WCG operates multiple locations across the United States and in Tokyo, Japan, and has established a strategic partnership with InformedDNA.
ConvaTec Inc. is a global medical products and technologies company headquartered in Bridgewater, New Jersey. Founded in 1978, it specializes in the management of chronic conditions through its diverse range of products. ConvaTec holds leading market positions in advanced wound care, ostomy care, continence and critical care, as well as infusion devices. The company's offerings are designed to provide significant clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes, and reduced overall costs of care. As a subsidiary of Convatec Group Plc, ConvaTec is committed to enhancing the quality of life for patients worldwide through innovative solutions.
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.
PanOptica, Inc. is a biopharmaceutical company focused on developing innovative topical eye drops for the treatment of sight-threatening eye diseases associated with abnormal or leaky blood vessels. Based in Mount Arlington, New Jersey, the company was founded in 2009 and is known for its lead compound, PAN-90806, a small-molecule selective VEGF receptor antagonist. This treatment shows potential for addressing conditions such as wet age-related macular degeneration and diabetic retinopathy, which can lead to significant vision loss. By seeking to license and develop new therapeutics, PanOptica aims to enhance the effectiveness of existing treatments and provide solutions for previously untreatable disorders, ultimately improving patients' vision and quality of life.
IVERIC bio is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, particularly age-related and orphan retinal conditions. The company is advancing several candidates, including Fovista, which has completed Phase IIb clinical trials as a combination treatment with anti-VEGF drugs for wet age-related macular degeneration (wet AMD). Additionally, IVERIC bio is developing ARC1905, a selective inhibitor of complement factor C5, which has completed Phase I/IIa clinical trials aimed at treating wet AMD. Founded in 2007 and headquartered in New York, IVERIC bio is dedicated to addressing unmet medical needs in the field of eye care.
Private Equity Round in 2013
IVERIC bio is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, particularly age-related and orphan retinal conditions. The company is advancing several candidates, including Fovista, which has completed Phase IIb clinical trials as a combination treatment with anti-VEGF drugs for wet age-related macular degeneration (wet AMD). Additionally, IVERIC bio is developing ARC1905, a selective inhibitor of complement factor C5, which has completed Phase I/IIa clinical trials aimed at treating wet AMD. Founded in 2007 and headquartered in New York, IVERIC bio is dedicated to addressing unmet medical needs in the field of eye care.
Private Equity Round in 2013
IVERIC bio is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, particularly age-related and orphan retinal conditions. The company is advancing several candidates, including Fovista, which has completed Phase IIb clinical trials as a combination treatment with anti-VEGF drugs for wet age-related macular degeneration (wet AMD). Additionally, IVERIC bio is developing ARC1905, a selective inhibitor of complement factor C5, which has completed Phase I/IIa clinical trials aimed at treating wet AMD. Founded in 2007 and headquartered in New York, IVERIC bio is dedicated to addressing unmet medical needs in the field of eye care.
Private Equity Round in 2013
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.
Private Equity Round in 2013
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.
Private Equity Round in 2012
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.
Tobira Therapeutics, Inc. is a biotechnology company focused on the research, development, and commercialization of antiviral compounds aimed at treating serious infectious diseases. Founded in 2006 and based in Princeton, New Jersey, the company specializes in the development of TBR-652 and TBR-220 antagonists, which are designed for the treatment of HIV/AIDS, hepatitis, and other related infectious conditions. Through its innovative approach, Tobira Therapeutics aims to address critical health challenges associated with these diseases.
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.
IVERIC bio is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, particularly age-related and orphan retinal conditions. The company is advancing several candidates, including Fovista, which has completed Phase IIb clinical trials as a combination treatment with anti-VEGF drugs for wet age-related macular degeneration (wet AMD). Additionally, IVERIC bio is developing ARC1905, a selective inhibitor of complement factor C5, which has completed Phase I/IIa clinical trials aimed at treating wet AMD. Founded in 2007 and headquartered in New York, IVERIC bio is dedicated to addressing unmet medical needs in the field of eye care.
Lux Biosciences, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing medications for ophthalmic diseases. Founded in 2005, the company offers a range of innovative treatments, including LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye for a duration of one year. Additionally, Lux Biosciences produces Luveniq, an oral formulation of the calcineurin inhibitor voclosporin, as well as LX212, a bioerodible polymer implant containing voclosporin. The company also provides LX214, a topical formulation of voclosporin designed to address dry eye conditions. Through these products, Lux Biosciences aims to improve treatment options for serious eye diseases.
IVERIC bio is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, particularly age-related and orphan retinal conditions. The company is advancing several candidates, including Fovista, which has completed Phase IIb clinical trials as a combination treatment with anti-VEGF drugs for wet age-related macular degeneration (wet AMD). Additionally, IVERIC bio is developing ARC1905, a selective inhibitor of complement factor C5, which has completed Phase I/IIa clinical trials aimed at treating wet AMD. Founded in 2007 and headquartered in New York, IVERIC bio is dedicated to addressing unmet medical needs in the field of eye care.
Lux Biosciences, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing medications for ophthalmic diseases. Founded in 2005, the company offers a range of innovative treatments, including LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye for a duration of one year. Additionally, Lux Biosciences produces Luveniq, an oral formulation of the calcineurin inhibitor voclosporin, as well as LX212, a bioerodible polymer implant containing voclosporin. The company also provides LX214, a topical formulation of voclosporin designed to address dry eye conditions. Through these products, Lux Biosciences aims to improve treatment options for serious eye diseases.
Lux Biosciences, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing medications for ophthalmic diseases. Founded in 2005, the company offers a range of innovative treatments, including LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye for a duration of one year. Additionally, Lux Biosciences produces Luveniq, an oral formulation of the calcineurin inhibitor voclosporin, as well as LX212, a bioerodible polymer implant containing voclosporin. The company also provides LX214, a topical formulation of voclosporin designed to address dry eye conditions. Through these products, Lux Biosciences aims to improve treatment options for serious eye diseases.
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.
Private Equity Round in 2005
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.